[¹⁸F]TFB PET/CT misses intense [¹²⁴I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2024-10-08 DOI:10.1186/s13550-024-01138-x

Philipp Backhaus, Keith S Pentlow, Alan L Ho, Audrey Mauguen, James A Fagin, Naga Vara Kishore Pillarsetty, Serge K Lyashchenko, Eva Burnazi, Ronald A Ghossein, Shalini Chhabra, Murad Abusamra, Steven M Larson, Heiko Schöder, Joseph O'Donoghue, Wolfgang Weber, Ravinder K Grewal

{"title":"[18F]TFB PET/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.","authors":"Philipp Backhaus, Keith S Pentlow, Alan L Ho, Audrey Mauguen, James A Fagin, Naga Vara Kishore Pillarsetty, Serge K Lyashchenko, Eva Burnazi, Ronald A Ghossein, Shalini Chhabra, Murad Abusamra, Steven M Larson, Heiko Schöder, Joseph O'Donoghue, Wolfgang Weber, Ravinder K Grewal","doi":"10.1186/s13550-024-01138-x","DOIUrl":null,"url":null,"abstract":"Background: Fluorine 18-labelled tetrafluoroborate ([18F]TFB) is a substrate for the sodium/iodide symporter. In thyroid cancer, [18F]TFB-PET/CT may be an alternative to iodine imaging to evaluate the extent of disease, eligibility for radioiodine treatment, and success of redifferentiation therapies. We report the results of a pilot study to determine tumor uptake of [18F]TFB and compare its properties to [124I]IodinePET/CT in patients with metastatic thyroid cancer.Methods: Five patients were included in a prospective study. All patients received PET/CT 1 h after injection of 356 ± 12 MBq [18F]TFB and were given 230 ± 9 MBq [124I]Iodine orally on the same day, followed by PET/CT after 48 h. Before redifferentiation therapy, patients underwent an additional baseline [124I]Iodine PET/CT. Cases were analyzed by two board-certified specialists. Detection rates and Spearman correlation for [18F]TFB and [124I]Iodine were calculated.Results: Three patients had poorly differentiated thyroid cancer and received trametinib in a redifferentiation trial. Two patients had papillary thyroid cancer and did not receive redifferentiation therapy. Of the 33 lesions seen before/without redifferentiation therapy, 19 (58%) were visible on [18F]TFB and 30 (91%) on [124I]Iodine imaging. In the patients who underwent redifferentiation therapy, 48 lesions were newly seen on [124I]Iodine PET/CT with a median SUVmax of 3.3 (range, 0.4-285.0). All of these lesions were [18F]TFB-negative.Conclusion: [18F]TFB failed to predict radioactive iodine uptake in patients with poorly differentiated thyroid cancer who underwent redifferentiation therapy with trametinib. It is unclear whether such discrepancies may also occur in other redifferentiation therapies or may even be encountered in redifferentiation-naïve thyroid cancer.Trial registration number: NCT03196518, registered on June 22, 2017.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"91"},"PeriodicalIF":3.1000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11461403/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01138-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Fluorine 18-labelled tetrafluoroborate ([¹⁸F]TFB) is a substrate for the sodium/iodide symporter. In thyroid cancer, [¹⁸F]TFB-PET/CT may be an alternative to iodine imaging to evaluate the extent of disease, eligibility for radioiodine treatment, and success of redifferentiation therapies. We report the results of a pilot study to determine tumor uptake of [¹⁸F]TFB and compare its properties to [¹²⁴I]IodinePET/CT in patients with metastatic thyroid cancer.

Methods: Five patients were included in a prospective study. All patients received PET/CT 1 h after injection of 356 ± 12 MBq [¹⁸F]TFB and were given 230 ± 9 MBq [¹²⁴I]Iodine orally on the same day, followed by PET/CT after 48 h. Before redifferentiation therapy, patients underwent an additional baseline [¹²⁴I]Iodine PET/CT. Cases were analyzed by two board-certified specialists. Detection rates and Spearman correlation for [¹⁸F]TFB and [¹²⁴I]Iodine were calculated.

Results: Three patients had poorly differentiated thyroid cancer and received trametinib in a redifferentiation trial. Two patients had papillary thyroid cancer and did not receive redifferentiation therapy. Of the 33 lesions seen before/without redifferentiation therapy, 19 (58%) were visible on [¹⁸F]TFB and 30 (91%) on [¹²⁴I]Iodine imaging. In the patients who underwent redifferentiation therapy, 48 lesions were newly seen on [¹²⁴I]Iodine PET/CT with a median SUV_max of 3.3 (range, 0.4-285.0). All of these lesions were [¹⁸F]TFB-negative.

Conclusion: [¹⁸F]TFB failed to predict radioactive iodine uptake in patients with poorly differentiated thyroid cancer who underwent redifferentiation therapy with trametinib. It is unclear whether such discrepancies may also occur in other redifferentiation therapies or may even be encountered in redifferentiation-naïve thyroid cancer.

Trial registration number: NCT03196518, registered on June 22, 2017.

查看原文本刊更多论文

[18F]TFB PET/CT 会错过转移性甲状腺癌再分化治疗后的强烈[124I]碘标记转移。

背景：氟18标记的四氟硼酸盐（[18F]TFB）是钠/碘交感器的底物。在甲状腺癌中，[18F]TFB-PET/CT 可替代碘成像来评估疾病的程度、接受放射性碘治疗的资格以及再分化疗法的成功率。我们报告了一项试验性研究的结果，该研究旨在确定转移性甲状腺癌患者对[18F]TFB的肿瘤摄取情况，并比较其与[124I]碘PET/CT的特性：方法：五名患者被纳入前瞻性研究。所有患者在注射 356 ± 12 MBq [18F]TFB 后 1 小时接受 PET/CT，并在同一天口服 230 ± 9 MBq [124I]碘，48 小时后接受 PET/CT。病例由两名获得医学会认证的专家进行分析。计算[18F]TFB和[124I]碘的检出率和斯皮尔曼相关性：结果：三名患者患有分化不良的甲状腺癌，并在一项再分化试验中接受了曲美替尼治疗。两名患者患有甲状腺乳头状癌，未接受再分化治疗。在接受再分化治疗前/未接受再分化治疗的33例病变中，19例（58%）在[18F]TFB成像中可见，30例（91%）在[124I]碘成像中可见。在接受再分化治疗的患者中，有 48 个病灶在[124I]碘 PET/CT 上新发现，中位 SUVmax 为 3.3（范围为 0.4-285.0）。所有这些病灶均为[18F]TFB阴性：结论：[18F]TFB无法预测接受曲美替尼再分化治疗的分化不良甲状腺癌患者的放射性碘摄取量。目前还不清楚这种差异是否也会发生在其他再分化疗法中，甚至可能发生在再分化疗法无效的甲状腺癌患者中：NCT03196518，注册于2017年6月22日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.